Top Headlines
Latest News
Analysis
Although it has been predicted that this will be a lean year for the approval and launch of blockbuster drugs this picture could all change if any of the anti-programmed death-1 (PD-1) antibodies under development make it to market.
Our Habitat for All Things Science
Clinical trial shows edited T cells can resist, fight HIV
Scientists have been able to engineer the T cells of HIV-infected patients to become resistant to the virus, and such cells were subsequently able to control HIV infection when patients were taken off of antiretroviral therapy (ART), including one patient whose blood levels of HIV became undetectable over the course of the phase I trial.
- Gene variant protecting against diabetes ‘holds clue to new therapies’ »
- Alzheimer’s risk gene produces antimetastatic protein »
- Chinese herbal medicine ingredient has new anti-inflammatory effects »
- Nanoparticle unsticks inflammatory cells »
- Be our guest? The right gut microflora can treat disease »
- Deep data dive reveals skin-deep target »
- Life sciences, engineering, physical sciences intersect as third biomed revolution »
- Antibody to clotting factor could prevent troubling side effects »
- ‘Antioxidant’ vitamin C may improve chemotherapy »
Featured Report
Opinion
- Human germline engineering: The mom’s not in the pictureMarch 04, 2014 | 3:17 PM | Posted by: Anette Breindl
- Biosimilar regulation: 1984 v. 2014February 19, 2014 | 9:06 PM | Posted by: Mari Serebrov
- Drug pricing: Are we paying for efficacy or innovation?February 12, 2014 | 11:12 PM | Posted by: Jennifer Boggs
- Happy Holidays! BioWorld’s 7th Annual Biotech Gift GuideFebruary 05, 2014 | 6:23 PM | Posted by: Marie Powers
- An Asia Strategy is Not OptionalOctober 30, 2013 | 1:09 PM | Posted by: Lynn Yoffee
